litlas
Log inCreate account

Marc S. Ernstoff

Active 1984–2025

Also published as
MARC S. ERNSTOFF · Marc S Ernstoff
115
Papers
35,518
Citations
84
h-index
111
i10-index

Citations

Citations per year for Marc S. Ernstoff1985: 5 citations1986: 12 citations1987: 8 citations1988: 5 citations1989: 7 citations1990: 3 citations1991: 7 citations1992: 3 citations1993: 11 citations1994: 18 citations1995: 18 citations1996: 14 citations1997: 13 citations1998: 39 citations1999: 35 citations2000: 36 citations2001: 57 citations2002: 85 citations2003: 70 citations2004: 70 citations2005: 63 citations2006: 72 citations2007: 73 citations2008: 65 citations2009: 116 citations2010: 125 citations2011: 129 citations2012: 150 citations2013: 168 citations2014: 152 citations2015: 281 citations2016: 332 citations2017: 432 citations2018: 459 citations2019: 1,301 citations2020: 1,672 citations2021: 1,663 citations2022: 1,368 citations2023: 1,056 citations2024: 1,620 citations2025: 756 citations2026: 19 citations

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 4,676 citing papers, 30.1% of this breakdownChina: 1,627 citing papers, 10.5% of this breakdownItaly: 892 citing papers, 5.7% of this breakdownGermany: 800 citing papers, 5.1% of this breakdownUnited Kingdom: 773 citing papers, 5% of this breakdownFrance: 692 citing papers, 4.4% of this breakdownAustralia: 517 citing papers, 3.3% of this breakdownCanada: 511 citing papers, 3.3% of this breakdownSpain: 452 citing papers, 2.9% of this breakdownJapan: 448 citing papers, 2.9% of this breakdownNetherlands: 415 citing papers, 2.7% of this breakdownSwitzerland: 362 citing papers, 2.3% of this breakdown
0%30.1%Other 21.8%

Institutions

Fields

  • Medicine69.8%
  • Immunology and Microbiology13.4%
  • Biochemistry, Genetics and Molecular Biology13%
  • Neuroscience0.8%
  • Engineering0.6%
  • Pharmacology, Toxicology and Pharmaceutics0.4%
  • Other2%

Topics

  • Cancer Immunotherapy and Biomarkers16.6%
  • Immunotherapy and Immune Responses6.6%
  • CAR-T cell therapy research6.3%
  • Immune Cell Function and Interaction3.8%
  • Cutaneous Melanoma Detection and Management3.3%
  • Melanoma and MAPK Pathways3.2%
  • Other60.2%

Coauthors

All papers

Open in search
  1. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update

    Authors: Bryan J. Schneider, Jarushka Naidoo, Bianca D. Santomasso, Christina Lacchetti, Sherry Adkins, Milan Anadkat, Michael B. Atkins, Kelly J. Brassil, Jeffrey M. Caterino, Ian Chau, Marianne J. Davies, Marc S. Ernstoff, Leslie Fecher, Monalisa Ghosh, Ishmael Jaiyesimi, Jennifer S. Mammen, Aung Naing, Loretta J. Nastoupil, Tanyanika Phillips, Laura D. Porter, Cristina A. Reichner, Carole Seigel, Jung-Min Song, Alexander Spira, Maria Suarez-Almazor, Umang Swami, John A. Thompson, Praveen Vikas, Yinghong Wang, Jeffrey S. Weber, Pauline Funchain, Kathryn Bollin - Journal of Clinical Oncology 2021 cited by 1,964

  2. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline

    Authors: Julie R. Brahmer, Christina Lacchetti, Bryan J. Schneider, Michael B. Atkins, Kelly Brassil, Jeffrey M. Caterino, Ian Chau, Marc S. Ernstoff, Jennifer M. Gardner, Pamela Ginex, Sigrun Hallmeyer, Jennifer Holter Chakrabarty, Natasha B. Leighl, Jennifer S. Mammen, David F. McDermott, Aung Naing, Loretta J. Nastoupil, Tanyanika Phillips, Laura Porter, Igor Puzanov, Cristina Reichner, Bianca Santomasso, Carole Seigel, Alexander I. Spira, María E. Suarez‐Almazor, Yinghong Wang, Jeffrey S. Weber, Jedd D. Wolchok, John A. Thompson - Journal of Clinical Oncology 2018 cited by 3,697

  3. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events

    Authors: Julie R. Brahmer, Hamzah Abu‐Sbeih, Paolo A. Ascierto, Jill Brufsky, Laura C. Cappelli, Frank B. Cortazar, David E. Gerber, Lamya Hamad, Eric Hansen, Douglas B. Johnson, Mario E. Lacouture, Gregory A. Masters, Jarushka Naidoo, Michele Nanni, Miguel‐Angel Perales, Igor Puzanov, Bianca Santomasso, Satish Shanbhag, Rajeev Sharma, Dimitra Skondra, Jeffrey A. Sosman, Michelle Turner, Marc S. Ernstoff - Journal for ImmunoTherapy of Cancer 2021 cited by 826

  4. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group

    Authors: on behalf of the Society for Immunotherapy of Cancer Toxicity Management Working Group, Igor Puzanov, Adi Diab, K. Abdallah, Clifton O. Bingham, Cynthia F. Brogdon, Ramona Dadu, Lamya Hamad, Sungjun Kim, Mario E. Lacouture, Nicole R. LeBoeuf, Dan Lenihan, C.D. Onofrei, Vickie R. Shannon, Rajeev Sharma, Ann W. Silk, Dimitra Skondra, María E. Suarez‐Almazor, Yinghong Wang, Kathleen E. Wiley, Howard L. Kaufman, Marc S. Ernstoff - Journal for ImmunoTherapy of Cancer 2017 cited by 1,984

  5. Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO Guideline

    Authors: Bianca D. Santomasso, Loretta J. Nastoupil, Sherry Adkins, Christina Lacchetti, Bryan J. Schneider, Milan Anadkat, Michael B. Atkins, Kelly J. Brassil, Jeffrey M. Caterino, Ian Chau, Marianne J. Davies, Marc S. Ernstoff, Leslie Fecher, Pauline Funchain, Ishmael Jaiyesimi, Jennifer S. Mammen, Jarushka Naidoo, Aung Naing, Tanyanika Phillips, Laura D. Porter, Cristina A. Reichner, Carole Seigel, Jung-Min Song, Alexander Spira, Maria Suarez-Almazor, Umang Swami, John A. Thompson, Praveen Vikas, Yinghong Wang, Jeffrey S. Weber, Kathryn Bollin, Monalisa Ghosh - Journal of Clinical Oncology 2021 cited by 376

  6. Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma

    Authors: Michael A. Postow, Jason Chesney, Anna C. Pavlick, Caroline Robert, Kenneth F. Grossmann, David F. McDermott, Gerald P. Linette, Nicolás Meyer, Jeffrey K. Giguere, Sanjiv S. Agarwala, Montaser Shaheen, Marc S. Ernstoff, David R. Minor, April K.S. Salama, Matthew H. Taylor, Patrick A. Ott, Linda M. Rollin, Christine E. Horak, Paul Gagnier, Jedd D. Wolchok, F. Stephen Hodi - New England Journal of Medicine 2015 cited by 2,763

  7. Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain

    Authors: Hussein A. Tawbi, Peter Forsyth, Alain P. Algazi, Omid Hamid, F. Stephen Hodi, Stergios J. Moschos, Nikhil I. Khushalani, Karl D. Lewis, Christopher D. Lao, Michael A. Postow, Michael B. Atkins, Marc S. Ernstoff, David A. Reardon, Igor Puzanov, Ragini R. Kudchadkar, Reena Thomas, Ahmad A. Tarhini, Anna C. Pavlick, Joel Jiang, Alexandre Avila, Sheena Demelo, Kim Margolin - New England Journal of Medicine 2018 cited by 1,321

  8. Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study

    Authors: Hussein A Tawbi, Peter A Forsyth, F Stephen Hodi, Alain P Algazi, Omid Hamid, Christopher D Lao, Stergios J Moschos, Michael B Atkins, Karl Lewis, Michael A Postow, Reena P Thomas, John Glaspy, Sekwon Jang, Nikhil I Khushalani, Anna C Pavlick, Marc S Ernstoff, David A Reardon, Ragini Kudchadkar, Ahmad Tarhini, Caroline Chung, Corey Ritchings, Piyush Durani, Margarita Askelson, Igor Puzanov, Kim A Margolin - The Lancet Oncology 2021 cited by 322

  9. NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020

    Authors: John A. Thompson, Bryan J. Schneider, Julie R. Brahmer, Stephanie Andrews, Philippe Armand, Shailender Bhatia, Lihua E. Budde, Luciano J. Costa, Marianne Davies, David Dunnington, Marc S. Ernstoff, Matthew J. Frigault, Benjamin H. Kaffenberger, Matthew A. Lunning, Suzanne McGettigan, Jordan P. McPherson, Nisha Mohindra, Jarushka Naidoo, Anthony J. Olszanski, Olalekan O. Oluwole, Sandip Pravin Patel, Nathan A. Pennell, Sunil Reddy, Mabel Ryder, Bianca Santomasso, Scott Shofer, Jeffrey A. Sosman, Yinghong Wang, Ryan Weight, Alyse Johnson-Chilla, Griselda Zuccarino-Catania, Anita M. Engh - Journal of the National Comprehensive Cancer Network 2020 cited by 486

  10. VISTA Is an Immune Checkpoint Molecule for Human T Cells

    Authors: J. Louise Lines, Eirini Pantazi, Justin Mak, Lorenzo F. Sempere, Li Wang, Samuel O’Connell, Sabrina Ceeraz, Arief A. Suriawinata, Shaofeng Yan, Marc S. Ernstoff, Randolph J. Noelle - Cancer Research 2014 cited by 500

  11. Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial

    Authors: F. Stephen Hodi, Jason Chesney, Anna C. Pavlick, Caroline Robert, Kenneth F. Grossmann, David F. McDermott, Gerald P. Linette, Nicolás Meyer, Jeffrey K. Giguere, Sanjiv S. Agarwala, Montaser Shaheen, Marc S. Ernstoff, David R. Minor, April K.S. Salama, Matthew H. Taylor, Patrick A. Ott, Christine E. Horak, Paul Gagnier, Joel Jiang, Jedd D. Wolchok, Michael A. Postow - The Lancet Oncology 2016 cited by 980

  12. Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology

    Authors: John A. Thompson, Bryan J. Schneider, Julie R. Brahmer, Stephanie Andrews, Philippe Armand, Shailender Bhatia, Lihua E. Budde, Luciano J. Costa, Marianne Davies, David Dunnington, Marc S. Ernstoff, Matthew J. Frigault, Brianna Hoffner, Christopher Hoimes, Mario E. Lacouture, Frederick L. Locke, Matthew A. Lunning, Nisha Mohindra, Jarushka Naidoo, Anthony J. Olszanski, Olalekan O. Oluwole, Sandip Pravin Patel, Sunil Reddy, Mabel Ryder, Bianca Santomasso, Scott Shofer, Jeffrey A. Sosman, Momen M. Wahidi, Yinghong Wang, Alyse Johnson-Chilla, Jillian L. Scavone - Journal of the National Comprehensive Cancer Network 2019 cited by 560

  13. T-cell CX3CR1 expression as a dynamic blood-based biomarker of response to immune checkpoint inhibitors

    Authors: Takayoshi Yamauchi, Toshifumi Hoki, Takaaki Oba, Vaibhav Jain, Hongbin Chen, Kristopher Attwood, Sebastiano Battaglia, Saby George, Gurkamal Chatta, Igor Puzanov, Carl Morrison, Kunle Odunsi, Brahm H. Segal, Grace K. Dy, Marc S. Ernstoff, Fumito Ito - Nature Communications 2021 cited by 187

  14. Immune-Checkpoint Protein VISTA Regulates Antitumor Immunity by Controlling Myeloid Cell–Mediated Inflammation and Immunosuppression

    Authors: Wenwen Xu, Juan Dong, Yongwei Zheng, Juan Zhou, Ying Yuan, Hieu Minh Ta, Halli E. Miller, Michael Olson, Kamalakannan Rajasekaran, Marc S. Ernstoff, Demin Wang, Subramaniam Malarkannan, Li Wang - Cancer Immunology Research 2019 cited by 186

  15. Resident and circulating memory T cells persist for years in melanoma patients with durable responses to immunotherapy

    Authors: Jichang Han, Yanding Zhao, Keisuke Shirai, Aleksey Molodtsov, Fred Kolling, Jan L. Fisher, Zhang Peisheng, Shaofeng Yan, Tyler G. Searles, Justin M. Bader, Jiang Gui, Chao Cheng, Marc S. Ernstoff, Mary Jo Turk, Christina V. Angeles - Nature Cancer 2021 cited by 148

  16. Arginase I–Producing Myeloid-Derived Suppressor Cells in Renal Cell Carcinoma Are a Subpopulation of Activated Granulocytes

    Authors: Paulo C. Rodrı́guez, Marc S. Ernstoff, Claudia Hernandez, Michael B. Atkins, Jovanny Zabaleta, Rosa A. Sierra, Augusto C. Ochoa - Cancer Research 2009 cited by 756

  17. ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapy

    Authors: Jared E. Lopes, Jan L. Fisher, Heather Flick, Chunhua Wang, Lei Sun, Marc S. Ernstoff, Juan C. Alvarez, Heather C. Losey - Journal for ImmunoTherapy of Cancer 2020 cited by 138

  18. Managing Metastatic Melanoma in 2022: A Clinical Review

    Authors: Benjamin Switzer, Igor Puzanov, Joseph J. Skitzki, Lamya Hamad, Marc S. Ernstoff - JCO Oncology Practice 2022 cited by 190

  19. Purity and yield of melanoma exosomes are dependent on isolation method

    Authors: Shin La Shu, Yunchen Yang, Cheryl Allen, Edward Hurley, Kaity Tung, Hans Minderman, Yun Wu, Marc S. Ernstoff - Journal of Extracellular Vesicles 2019 cited by 185

  20. Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational study

    Authors: Fangwen Zou, David M. Faleck, Anusha Shirwaikar Thomas, Jessica Harris, Deepika Satish, Xuemei Wang, Aline Charabaty, Marc S. Ernstoff, Isabella C. Glitza Oliva, Stephen B. Hanauer, Jennifer L. McQuade, Michel Obéid, Amishi Y. Shah, David M. Richards, Elad Sharon, Jedd D. Wolchok, John A. Thompson, Yinghong Wang - Journal for ImmunoTherapy of Cancer 2021 cited by 117

  21. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial

    Authors: Kim Margolin, Marc S. Ernstoff, Omid Hamid, Donald P. Lawrence, David F. McDermott, Igor Puzanov, Jedd D. Wolchok, Joseph I. Clark, Mario Sznol, Theodore F. Logan, Jon Richards, Tracy Michener, Ágnes Balogh, Kevin N. Heller, F. Stephen Hodi - The Lancet Oncology 2012 cited by 1,081

  22. Phase I Clinical Trial of Combination Propranolol and Pembrolizumab in Locally Advanced and Metastatic Melanoma: Safety, Tolerability, and Preliminary Evidence of Antitumor Activity

    Authors: Shipra Gandhi, Manu Pandey, Kristopher Attwood, Wenyan Ji, Agnieszka K. Witkiewicz, Erik S. Knudsen, Cheryl Allen, Joseph D. Tario, Paul K. Wallace, Carlos D. Cedeno, Maria Levis, Suzanne Stack, Pauline Funchain, Joseph J. Drabick, Mark J. Bucsek, Igor Puzanov, Hemn Mohammadpour, Elizabeth A. Repasky, Marc S. Ernstoff - Clinical Cancer Research 2020 cited by 144

  23. Assessment of the Safety of Pembrolizumab in Patients With HIV and Advanced Cancer—A Phase 1 Study

    Authors: Thomas S. Uldrick, Priscila Gonçalves, Maher Abdul‐Hay, Alisa J Claeys, Brinda Emu, Marc S. Ernstoff, Steven P. Fling, Lawrence Fong, Judith C. Kaiser, Andreanne M. Lacroix, Steve Y. Lee, Lisa Lundgren, Kathryn Lurain, Christopher Parsons, Sharavi Peeramsetti, Ramya Ramaswami, Elad Sharon, Mario Sznol, Chia-Ching Wang, Robert Yarchoan, Martin A. Cheever, for the Cancer Immunotherapy Trials Network (CITN)-12 Study Team - JAMA Oncology 2019 cited by 239

  24. Rechallenge patients with immune checkpoint inhibitors following severe immune-related adverse events: review of the literature and suggested prophylactic strategy

    Authors: John B.A.G. Haanen, Marc S. Ernstoff, Yinghong Wang, Alexander M. Menzies, Igor Puzanov, Petros Grivas, James Larkin, Solange Peters, John A. Thompson, Michel Obéid - Journal for ImmunoTherapy of Cancer 2020 cited by 167